OESOPHAGUS

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis

F Fiorica¹, D Di Bona², F Schepis³, A Licata⁵, L Shahied⁶, A Venturi⁴, A M Falchi⁴, A Craxì⁵, C Cammà²

¹ Cattedra di Radioterapia Oncologica, University of Modena e Reggio Emilia, Italy, and Servizio Radioterapia Oncologica, Azienda Ospedaliera Sant’Anna University of Ferrara, Italy
² Cattedra e Unità Operativa di Gastroenterologia University of Palermo, Italy, and IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
³ Dipartimento di Medicina Interna, University of Modena and Reggio Emilia, Italy
⁴ Cattedra di Radioterapia Oncologica, University of Modena e Reggio Emilia, Italy
⁵ Cattedra e Unità Operativa di Gastroenterologia, University of Palermo, Italy
⁶ Fox Chase Cancer Center, Philadelphia, PA, USA

Correspondence to:
Correspondence to:
Dr Calogero Cammà
Via Alcide De Gasperi 50, 90100 Palermo, Italy; camma{at}ibim.cnr.it

Background: The benefit of neoadjuvant chemoradiotherapy in oesophageal cancer has been extensively studied but data on survival are still equivocal.

Objective: To assess the effectiveness of chemoradiotherapy followed by surgery in the reduction of mortality in patients with resectable oesophageal cancer.

Methods: Computerised bibliographic searches of MEDLINE and CANCERLIT (1970–2002) were supplemented with hand searches of reference lists.

Study selection: Studies were included if they were randomised controlled trials (RCTs) comparing preoperative chemoradiotherapy plus surgery with surgery alone, and if they included patients with resectable histologically proven oesophageal cancer without metastatic disease. Six eligible RCTs were identified and included in the meta-analysis.

Data extraction: Data on study populations, interventions, and outcomes were extracted from each RCT according to the intention to treat method by three independent observers and combined using the DerSimonian and Laird method.

Results: Chemoradiotherapy plus surgery compared with surgery alone significantly reduced the three year mortality rate (odds ratio (OR) 0.53 (95% confidence interval (CI) 0.31–0.93); p = 0.03) (number needed to treat = 10). Pathological examination showed that preoperative chemoradiotherapy downstaged the tumour (that is, less advanced stage at pathological examination at the time of surgery) compared with surgery alone (OR 0.43 (95% CI 0.26–0.72); p = 0.001). The risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (OR 2.10 (95% CI 1.18–3.73); p = 0.01).

Conclusions: In patients with resectable oesophageal cancer, chemoradiotherapy plus surgery significantly reduces three year mortality compared with surgery alone. However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy. Further large scale multicentre RCTs may prove useful to substantiate the benefit on overall survival.

Abbreviations: CRT, chemoradiotherapy; RCTs, randomised controlled trials; OR, odds ratio; NNT, number of patients needed to treat; NNH, number of patients needed to harm; BED, biologically effective dose; CT, computed tomography

Keywords: chemoradiotherapy; oesophageal cancer; systematic review; meta-analysis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Robin Spiller
Gut 2004 53: 917. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Power, D.G., Ilson, D.H. (2009). Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Therapeutic Advances in Medical Oncology 1: 145-165 [Abstract]  
• MORITA, M., MASUDA, T., OKADA, S., YOSHINAGA, K., SAEKI, H., TOKUNAGA, E., ENDO, K., EMI, Y., KAKEJI, Y., MAEHARA, Y. (2009). Preoperative Chemoradiotherapy for Esophageal Cancer: Factors Associated with Clinical Response and Postoperative Complications. Anticancer Res 29: 2555-2562 [Abstract] [Full Text]  
• Stahl, M., Oliveira, J., On behalf of the ESMO Guidelines Working Group, (2009). Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv32-iv33 [Full Text]  
• Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H.-J., Riera-Knorrenschild, J., Langer, P., Engenhart-Cabillic, R., Bitzer, M., Konigsrainer, A., Budach, W., Wilke, H. (2009). Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. JCO 27: 851-856 [Abstract] [Full Text]  
• Tepper, J. E., O'Neil, B. (2009). Transition in Biology and Philosophy in the Treatment of Gastroesophageal Junction Adenocarcinoma. JCO 27: 836-837 [Full Text]  
• Bollschweiler, E., Metzger, R., Drebber, U., Baldus, S., Vallbohmer, D., Kocher, M., Holscher, A. H. (2009). Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20: 231-238 [Abstract] [Full Text]  
• Willett, C. G., Czito, B. G. (2009). Combined-modality Therapy for Esophageal Cancer. Am Soc Clin Oncol Ed Book 2009: 243-249 [Abstract] [Full Text]  
• Crane, S. J., Locke, G. R. III, Harmsen, W. S., Zinsmeister, A. R., Romero, Y., Talley, N. J. (2008). Survival Trends in Patients With Gastric and Esophageal Adenocarcinomas: A Population-Based Study. Mayo Clin Proc. 83: 1087-1094 [Abstract] [Full Text]  
• D'Journo, X.-B., Michelet, P., Dahan, L., Doddoli, C., Seitz, J.-F., Giudicelli, R., Fuentes, P. A., Thomas, P. A. (2008). Indications and outcome of salvage surgery for oesophageal cancer. Eur. J. Cardiothorac. Surg. 33: 1117-1123 [Abstract] [Full Text]  
• Khushalani, N. I. (2008). Cancer of the Esophagus and Stomach. Mayo Clin Proc. 83: 712-722 [Abstract] [Full Text]  
• Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., Kiel, K., Willett, C., Sugarbaker, D., Mayer, R. (2008). Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. JCO 26: 1086-1092 [Abstract] [Full Text]  
• D'Journo, X. B., Michelet, P., Papazian, L., Reynaud-Gaubert, M., Doddoli, C., Giudicelli, R., Fuentes, P. A., Thomas, P. A. (2008). Airway colonisation and postoperative pulmonary complications after neoadjuvant therapy for oesophageal cancer. Eur. J. Cardiothorac. Surg. 33: 444-450 [Abstract] [Full Text]  
• Chang, A. C., Ji, H., Birkmeyer, N. J., Orringer, M. B., Birkmeyer, J. D. (2008). Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer. Ann. Thorac. Surg. 85: 424-429 [Abstract] [Full Text]  
• Lennon, A. M., Penman, I. D. (2007). Endoscopic ultrasound in cancer staging. Br Med Bull 0: ldm033v1-18 [Abstract] [Full Text]  
• Crehange, G., Maingon, P., Peignaux, K., N'guyen, T. D., Mirabel, X., Marchal, C., Verrelle, P., Roullet, B., Bonnetain, F., Bedenne, L. (2007). Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Federation Francophone de Cancerologie Digestive 9102. JCO 25: 4895-4901 [Abstract] [Full Text]  
• Healy, L. A., Ryan, A. M., Gopinath, B., Rowley, S., Byrne, P. J., Reynolds, J. V. (2007). Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophagogastric junction.. J. Thorac. Cardiovasc. Surg. 134: 1284-1291 [Abstract] [Full Text]  
• Bruzzi, J. F., Munden, R. F., Truong, M. T., Marom, E. M., Sabloff, B. S., Gladish, G. W., Iyer, R. B., Pan, T.-S., Macapinlac, H. A., Erasmus, J. J. (2007). PET/CT of Esophageal Cancer: Its Role in Clinical Management. RadioGraphics 27: 1635-1652 [Abstract] [Full Text]  
• Kang, S. Y., Han, J. H., Lee, K. J., Choi, J.-H., Park, J. I., Kim, H. I., Lee, H.-W., Jang, J. H., Park, J. S., Kim, H. C., Kang, S., Oh, Y. T., Chun, M., Kim, J. H., Sheen, S. S., Lim, H.-Y. (2007). Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy. Clin. Cancer Res. 13: 4146-4153 [Abstract] [Full Text]  
• Steyerberg, E. W., Neville, B., Weeks, J. C., Earle, C. C. (2007). Referral Patterns, Treatment Choices, and Outcomes in Locoregional Esophageal Cancer: A Population-Based Analysis of Elderly Patients. JCO 25: 2389-2396 [Abstract] [Full Text]  
• Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J.-F., Herr, J.-P., Paillot, B., Arveux, P., Bonnetain, F., Binquet, C. (2007). Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102. JCO 25: 1160-1168 [Abstract] [Full Text]  
• Graham, A. J., Shrive, F. M., Ghali, W. A., Manns, B. J., Grondin, S. C., Finley, R. J., Clifton, J. (2007). Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. Ann. Thorac. Surg. 83: 1257-1264 [Abstract] [Full Text]  
• Gee, D. W., Rattner, D. W. (2007). Management of Gastroesophageal Tumors. The Oncologist 12: 175-185 [Abstract] [Full Text]  
• Lagarde, S. M., ten Kate, F. J.W., Reitsma, J. B., Busch, O. R.C., van Lanschot, J. J. B. (2006). Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction. JCO 24: 4347-4355 [Abstract] [Full Text]  
• Reynolds, J. V., Ravi, N., Hollywood, D., Kennedy, M. J., Rowley, S., Ryan, A., Hughes, N., Carey, M., Byrne, P. (2006). Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J. Thorac. Cardiovasc. Surg. 132: 549-555 [Abstract] [Full Text]  
• Hayashida, Y., Honda, K., Osaka, Y., Hara, T., Umaki, T., Tsuchida, A., Aoki, T., Hirohashi, S., Yamada, T. (2005). Possible Prediction of Chemoradiosensitivity of Esophageal Cancer by Serum Protein Profiling. Clin. Cancer Res. 11: 8042-8047 [Abstract] [Full Text]  
• Pasini, F., de Manzoni, G., Pedrazzani, C., Grandinetti, A., Durante, E., Gabbani, M., Tomezzoli, A., Griso, C., Guglielmi, A., Pelosi, G., Maluta, S., Cetto, G. L., Cordiano, C. (2005). High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 16: 1133-1139 [Abstract] [Full Text]  
• Stahl, M., Stuschke, M., Lehmann, N., Meyer, H.-J., Walz, M. K., Seeber, S., Klump, B., Budach, W., Teichmann, R., Schmitt, M., Schmitt, G., Franke, C., Wilke, H. (2005). Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus. JCO 23: 2310-2317 [Abstract] [Full Text]  
• (2004). Other articles noted. Evid. Based Med. 9: e5-e5 [Full Text]  

eLetters:

Read all eLetters

The weakest link

Steven R. DeMeester

Gut Online, 11 Aug 2004 [Full text]